TP53 and prostate carcinoma: Since Skp2-knockout mice are viable and fertile [40], SKP2 may serve as an “Achilles’ heel” type of drug target to effectively prevent or treat pRB, p53 and/or PTEN deficient prostate cancer potentially with less toxicity.